Agile Therapeutics (AGRX) Sees Unusually-High Trading Volume

Agile Therapeutics Inc (NASDAQ:AGRX) shares saw unusually-strong trading volume on Monday . Approximately 2,993,109 shares changed hands during trading, an increase of 972% from the previous session’s volume of 279,165 shares.The stock last traded at $0.91 and had previously closed at $0.89.

Several research analysts have recently weighed in on AGRX shares. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Agile Therapeutics in a research report on Friday, January 11th. Maxim Group started coverage on shares of Agile Therapeutics in a research report on Thursday, November 29th. They set a “buy” rating and a $3.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $3.33.

The stock has a market cap of $30.60 million, a P/E ratio of -0.99 and a beta of 0.32.



A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in Agile Therapeutics by 15.7% in the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after buying an additional 18,038 shares during the last quarter. Acadian Asset Management LLC lifted its position in Agile Therapeutics by 260.7% in the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after buying an additional 226,255 shares during the last quarter. Renaissance Technologies LLC lifted its position in Agile Therapeutics by 76.3% in the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after buying an additional 343,290 shares during the last quarter. Finally, Fosun International Ltd purchased a new stake in Agile Therapeutics during the third quarter worth about $180,000. 41.92% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Agile Therapeutics (AGRX) Sees Unusually-High Trading Volume” was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://dakotafinancialnews.com/2019/02/12/agile-therapeutics-agrx-sees-unusually-high-trading-volume.html.

About Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Read More: What is the strike price in options trading?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply